中基长寿科学(00767.HK) 公布，公司之间接非全资附属中骊与北京三有利订立技术推广协议，北京三有利和中骊将开展技术推广合作。
双方会就异体人牙髓间充质干细胞注射液治疗牙周炎项目，在海南省琼海市博鳌镇博鳌乐城国际医疗旅游先行区经批准后开展技术应用推广服务相关事宜。
牙髓干细胞项目在获得先行区技术合规批准和收费许可后，北京三有利将向合作医疗机构、合作代理商业机构推荐中骊作为牙髓干细胞项目技术应用推广服务商、在全球范围内按照国家法律法规要求开展该专案技术转化应用的推广服务，协同北京三有利及其合作方共同开展牙髓干细胞项目的技术推广和商业化落地，包括但不限于专案宣传推广及市场化营运拓展。
北京三有利关注于干细胞与生物医药研发，核心业务包括细胞治疗药物开发及GMP细胞制备。(sl/j)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.